Moleculent, a Stockholm-based life sciences technology company pioneering functional profiling to map cell-cell communication at scale in human tissue, has closed a $20 million financing round led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners, Eir Ventures, and other existing investors. The funding will support expansion of the company’s Techstart Early Access Program, accelerate U.S. commercial operations, and drive the commercial launch of its instrument platform.
Moleculent’s platform is the first to directly measure cell-cell interactions in clinical tissue at scale, addressing a fundamental gap in biological research. For years, researchers could see where cells are and what they express, but could not observe how they actually communicate within intact tissue. The company’s proprietary Proximity Ligation Assay detects cell-cell interactions in their native environment at high resolution, while simultaneously enabling cell typing through protein detection to provide full tissue context. To make the technology accessible to translational labs globally, Moleculent is developing an automated instrument enabling large-scale studies with high reproducibility and minimal hands-on time.
As part of the financing, Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners, has joined the Moleculent Board of Directors. Dahlberg brings more than 20 years of international management experience in life sciences, having held leadership roles at Life Technologies and Qiagen and previously led Cell Biology and Sample Preparation at Thermo Fisher Scientific.
KEY QUOTES:
“The market is telling us it’s ready. We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the US. This new funding allows us to move more aggressively as we work to put this platform into the hands of the scientists decoding the cellular conversations that drive human disease.”
Olle Ericsson, PhD, Co-Founder and CEO, Moleculent
“We have evaluated platforms across the life sciences tools landscape for years, and Moleculent stands out as truly category-defining. The company’s approach to directly mapping cell-cell communication has the potential to transform how researchers study disease and develop therapies.”
Ole Dahlberg, Managing Partner, Rubicon Healthcare Partners
“For years, we’ve been able to see where cells are and what they express, but we couldn’t see how they actually talk to each other in the tissue. Moleculent changes that completely, this is the kind of tool that reshapes entire research programs.”
Nigel Jamieson, Professor of Pancreatic and Liver Surgery, University of Glasgow
